about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
Company profile
Ticker
KOD
Exchange
Website
CEO
Victor Perlroth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Oligasis, LLC
SEC CIK
Corporate docs
IRS number
270476525
KOD stock data
Latest filings (excl ownership)
8-K
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
14 Nov 23
8-K
Other Events
6 Nov 23
8-K
Departure of Directors or Certain Officers
17 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights
14 Aug 23
8-K
Results of Operations and Financial Condition
24 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 23
EFFECT
Notice of effectiveness
5 Jun 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 351.99 mm | 351.99 mm | 351.99 mm | 351.99 mm | 351.99 mm | 351.99 mm |
Cash burn (monthly) | 11.00 mm | (no burn) | 18.17 mm | 24.00 mm | 10.92 mm | 14.75 mm |
Cash used (since last report) | 65.83 mm | n/a | 108.72 mm | 143.63 mm | 65.36 mm | 88.28 mm |
Cash remaining | 286.16 mm | n/a | 243.28 mm | 208.36 mm | 286.63 mm | 263.71 mm |
Runway (months of cash) | 26.0 | n/a | 13.4 | 8.7 | 26.2 | 17.9 |
Institutional ownership, Q3 2023
80.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 98 |
Opened positions | 14 |
Closed positions | 45 |
Increased positions | 35 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 72.75 bn |
Total shares | 42.23 mm |
Total puts | 9.70 k |
Total calls | 100.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 17.31 mm | $31.16 bn |
BLK Blackrock | 4.47 mm | $8.05 bn |
Millennium Management | 1.71 mm | $3.08 bn |
Acadian Asset Management | 1.64 mm | $2.95 mm |
Vanguard | 1.63 mm | $2.94 bn |
Newtyn Management | 1.61 mm | $2.90 bn |
Silverarc Capital Management | 1.11 mm | $2.01 bn |
ICONIQ Capital | 1.02 mm | $1.83 bn |
D. E. Shaw & Co. | 996.13 k | $1.79 bn |
Renaissance Technologies | 792.93 k | $1.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun 23 | Bancroft Charles A | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Bassil I Dahiyat | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Profusek Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Levy Richard S | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
30 Jun 23 | Yang Taiyin | Stock Option Common Stock | Grant | Acquire A | No | No | 6.9 | 40,000 | 276.00 k | 40,000 |
News
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
28 Mar 24
Kodiak Sciences Q4 EPS $(1.13) Misses $(0.77) Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
Preview: Kodiak Sciences's Earnings
27 Mar 24
Press releases
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
26 Mar 24
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
30 Jan 24
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
4 Jan 24